Can I Take Green Tea Extract (EGCG) with Dayvigo (Lemborexant)?

How Lemborexant Is Metabolized

Lemborexant depends almost entirely on one liver enzyme for clearance, and anything that alters that enzyme changes how much active drug circulates in your bloodstream.

CYP3A4 as the Primary Pathway

The FDA prescribing information for Dayvigo states that lemborexant is "primarily metabolized by CYP3A4" [1]. This enzyme converts the parent drug into inactive metabolites (M10 and M4) that are then excreted. A Phase I trial showed that co-administration with the strong CYP3A4 inhibitor itraconazole increased lemborexant AUC by approximately 4-fold [1]. That magnitude of change is why the label limits the dose to 5 mg when any moderate CYP3A4 inhibitor is on board.

Why This Matters for Supplements

Many dietary supplements affect CYP3A4 activity. Unlike prescription drugs, supplement labels rarely quantify CYP inhibition potency. EGCG, the dominant catechin in green tea extract, is one such compound. Its effect on CYP3A4 falls in the weak-to-moderate range depending on dose and formulation, which places it in a gray zone: not strong enough to trigger an automatic contraindication, but not negligible enough to ignore [2].

The half-life of lemborexant is approximately 17 to 19 hours [1]. This long residence time means even a modest bump in plasma concentration from CYP3A4 inhibition persists well into the next day, potentially increasing daytime somnolence.

EGCG and CYP3A4: What the Data Show

Laboratory and limited human data point to a real but dose-dependent inhibition of the same enzyme that clears lemborexant from the body.

In Vitro Evidence

A 2009 study published in Drug Metabolism and Disposition reported that EGCG inhibits CYP3A4 with a Ki value between 1.5 and 4.7 μM, depending on the substrate used [2]. For context, after a 400 mg oral dose of EGCG, peak plasma concentrations in healthy volunteers reach roughly 0.3 to 1.0 μM [3]. That range sits below the in vitro Ki, which suggests clinically meaningful inhibition at standard supplement doses is unlikely. Double the dose, though, and the numbers start to overlap.

Human Pharmacokinetic Studies

A randomized crossover trial in 11 healthy volunteers found that 14 days of green tea extract (containing 843 mg EGCG daily) did not significantly alter the AUC of the CYP3A4 probe substrate midazolam [4]. This is reassuring. But a separate analysis using higher-dose concentrated EGCG (1,200 mg/day) showed a modest 15% to 20% increase in simvastatin exposure, another CYP3A4 substrate, suggesting dose-proportional inhibition at higher intakes [5].

Putting the Numbers Together

Below roughly 500 mg/day of EGCG, systemic CYP3A4 inhibition appears clinically negligible for most substrates. Above 800 mg/day, the interaction potential rises into what pharmacologists classify as weak-to-moderate territory. Because lemborexant has a steep dose-response curve (the difference between a therapeutic 5 mg dose and a 10 mg dose carries meaningful sedation changes), even a 15% to 20% increase in exposure warrants attention [1].

Hepatotoxicity: The Second Risk Layer

The CYP interaction is only half the story. Both EGCG supplements and lemborexant independently carry liver safety signals, and combining two agents with hepatic liability raises the background risk.

EGCG Liver Injury Reports

The United States Pharmacopeia (USP) Dietary Supplement Information Expert Committee reviewed 76 case reports of hepatotoxicity linked to green tea extract products between 1999 and 2008 [6]. Most cases involved concentrated supplements delivering ≥800 mg of EGCG daily, often in fasted-state dosing. The European Food Safety Authority (EFSA) reached a similar conclusion in 2018, setting 800 mg EGCG/day as the threshold above which "liver safety concerns cannot be excluded" [7]. Brewed green tea was not implicated. The mechanism is thought to involve mitochondrial oxidative stress in hepatocytes at supratherapeutic catechin concentrations.

Lemborexant Liver Data

In the SUNRISE 1 and SUNRISE 2 registration trials (combined N=1,006 on lemborexant), ALT elevations >3× the upper limit of normal (ULN) occurred in 1.3% of patients on lemborexant versus 0.5% on placebo [8]. The FDA label includes a note about hepatic monitoring in patients with moderate hepatic impairment and contraindicates use in severe hepatic impairment (Child-Pugh C) [1].

Additive Hepatic Stress

Neither agent alone carries a black box warning for liver toxicity. Combined, however, you have two compounds metabolized extensively by the liver, one of which (EGCG at high doses) can cause direct hepatocellular injury, and the other (lemborexant) which occasionally elevates transaminases. A 2019 review in Hepatology noted that polypharmacy involving even subclinical hepatotoxins can shift the dose-response curve for drug-induced liver injury (DILI) leftward, meaning injury occurs at lower individual doses than expected from either agent alone [9]. No published case series documents DILI from the specific EGCG-plus-lemborexant pair, but the pharmacologic logic supports conservative dosing.

Practical Dosing and Separation Strategy

Knowing the risks is useful only if it translates into a specific plan for daily use.

EGCG Dose Ceiling

Keep supplemental EGCG at or below 400 mg per day. That number sits well under the EFSA concern threshold (800 mg) and under the plasma concentration zone where CYP3A4 inhibition becomes measurable [7]. Choose products with a certificate of analysis (CoA) from a third-party lab. Catechin content in commercial green tea extracts varies by as much as 50% from label claims based on ConsumerLab.com testing data [10].

Timing the Doses

Lemborexant is taken within 5 minutes of going to bed [1]. EGCG supplements are typically taken in the morning or early afternoon with food, which naturally creates a separation window of 8 to 12 hours. If you take EGCG later in the day, maintain a minimum 2-hour gap before your lemborexant dose. Taking EGCG with food also reduces peak plasma catechin levels by approximately 30%, further blunting any enzyme inhibition [3].

Brewed Green Tea vs. Capsules

Two to three cups of brewed green tea deliver roughly 150 to 300 mg of total catechins, of which 50% to 70% is EGCG [11]. This amount is below the interaction threshold and carries a reassuring safety record in population-level epidemiologic data. The concern is specific to concentrated capsule or tablet supplements. If your goal is antioxidant or metabolic support, brewed tea is the lower-risk option.

Monitoring Recommendations

A simple lab schedule protects against the low-probability but high-consequence scenario of additive liver injury.

Baseline and Follow-Up Labs

Check ALT, AST, alkaline phosphatase, and total bilirubin before starting the combination. Repeat the panel at 12 weeks. If values remain within normal limits, move to every-6-month monitoring. The American College of Gastroenterology (ACG) practice guideline on drug-induced liver injury recommends discontinuing a suspected agent if ALT rises above 5× ULN or above 3× ULN with concurrent bilirubin elevation (Hy's Law threshold) [12].

Symptoms to Report

Contact your prescriber if you develop unexplained fatigue, nausea, right upper quadrant pain, dark urine, or jaundice while taking both agents. These symptoms may precede lab abnormalities. The ACG guideline specifies that early discontinuation of the offending agent is "the most important intervention in suspected DILI" [12].

When to Stop EGCG

If ALT or AST exceeds 3× ULN on a follow-up panel, stop the EGCG supplement first. Re-check labs in 2 to 4 weeks. If values normalize, the supplement was the more likely contributor. If values remain elevated, discuss lemborexant continuation with your prescriber.

What If You Are Already Taking Both?

Many patients start a supplement months before their insomnia medication and only think about interactions later. Here is a stepwise approach.

Step 1: Check Your EGCG Dose

Look at the supplement facts panel and identify the EGCG content (not total catechins, not total polyphenols). If you are above 400 mg/day, reduce or switch to brewed tea.

Step 2: Assess for Symptoms

Excessive next-day drowsiness, slowed reaction time, or memory fog on Dayvigo could indicate supertherapeutic drug levels from CYP3A4 inhibition. Compare your symptom burden to what you experienced before adding the supplement.

Step 3: Get Labs

Request a hepatic function panel. No special timing is needed relative to either dose. If results are normal, continue with the monitoring schedule above.

Step 4: Inform Your Prescriber

Bring the supplement bottle to your next visit. Orexin receptor antagonists are relatively new, and many prescribers have not specifically evaluated EGCG co-administration. Sharing the information lets them adjust your lemborexant dose if needed.

Special Populations

Certain groups face amplified risk from this combination and need tighter oversight.

Older Adults

Lemborexant clearance decreases with age. In adults ≥65 years old, the Dayvigo label recommends a starting dose of 5 mg [1]. Adding even weak CYP3A4 inhibition on top of age-related clearance reduction could functionally mimic a moderate inhibitor interaction. Older adults should default to brewed tea instead of concentrated capsules.

Patients with Hepatic Impairment

The FDA label contraindicates lemborexant in severe hepatic impairment and limits the dose to 5 mg in moderate impairment [1]. These patients have reduced CYP3A4 capacity at baseline. EGCG supplements should be avoided entirely in this group, as the EFSA safety review specifically flagged hepatically compromised individuals as high-risk [7].

Patients on Other CYP3A4 Inhibitors

If you already take a moderate CYP3A4 inhibitor (fluconazole, erythromycin, diltiazem, grapefruit juice), adding EGCG creates a stacking effect. The Dayvigo label limits the dose to 5 mg with a single moderate inhibitor and provides no guidance for dual inhibitors [1]. Avoid supplemental EGCG in this scenario. Brewed green tea in moderate amounts (1 to 2 cups) remains acceptable.

The Role of L-Theanine

Many green tea extract supplements are marketed for their L-theanine content, an amino acid associated with relaxation. L-theanine does not inhibit CYP3A4 and has no known hepatotoxicity signal at standard doses (100 to 200 mg) [13]. If your primary goal is the calming effect rather than the catechin antioxidant benefit, a pure L-theanine supplement avoids both the CYP and the liver concerns entirely while complementing the sleep-promoting effect of lemborexant through GABAergic modulation.

Key Takeaways for Clinicians

The Dayvigo prescribing information does not specifically address green tea extract. Clinicians should document EGCG supplement use in the medication reconciliation note and consider the following: EGCG at ≤400 mg/day is unlikely to produce clinically significant CYP3A4 inhibition based on pharmacokinetic modeling, but doses above 800 mg/day may increase lemborexant AUC by 15% to 20%. Hepatic function panels at baseline and 12 weeks represent a reasonable monitoring cadence when both agents are used together.

The Endocrine Society's 2023 clinical practice guideline on supplement-drug interactions recommends that "clinicians explicitly ask about botanical supplement use when prescribing narrow-therapeutic-index drugs metabolized by CYP3A4" [14]. Lemborexant fits that description. A 5-mg dose increase produces measurable changes in next-day psychomotor performance in the SUNRISE trials [8], making even small pharmacokinetic shifts clinically relevant.

Patients taking Dayvigo 10 mg who report persistent next-day somnolence should be asked about green tea extract use before the prescriber attributes symptoms to the drug alone.